-
2026-09-11HiDiamond and Nerviano Medical Sciences Enter Collaboration and License Agreement for NMS-173, a Potential Best-in-Class Covalent Dual mIDH1/2 Inhibitor
HiDiamond and Nerviano Medical Sciences Enter Collaboration and License Agreement for NMS-173, a Potential Best-in-Class Covalent Dual mIDH1/2 Inhibitor -
2026-03-10HiDiamond completed nearly RMB 100 million in Pre-A round financing
HiDiamond completed nearly RMB 100 million in Pre-A round financing -
2023-12-29Founder Dr. Ying Shao was awarded the "2023 Gusu Leading Talent for Innovation and Entrepreneurship"
Founder Dr. Ying Shao was awarded the "2023 Gusu Leading Talent for Innovation and Entrepreneurship" -
2023-09-08Breaking | HiDiamond's first innovative product was officially approved for clinical trials
HiDiamond's first innovative product, HiD21 — a high‑specificity epigenetic therapeutic‑target inhibitor, has had its Investigational New Drug (IND) application approved.
